Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...

The market for GLP-1 drugs is projected to reach $180 billion in 2034, according to Morningstar Equity Research. Current ...

Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

Research links variations in the gene GRIN2A to a higher risk of developing schizophrenia and other forms of mental illness.

Lilly reports Phase 3 CLL results showing Jaypirca matched and improved on Imbruvica across response rates and early progression trends, with safety consistent between treatments.

Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a ...

On December 3, Guggenheim raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,163 from $1,036 and kept a Buy ...

Jelly Roll, Ashley Tisdale, Chrissy Teigen, Meghan Trainor and more celebs who've talked about semaglutide drugs including ...

The 2026 update to the ADA’s Standards of Care in Diabetes introduces new guidance on a wide range of topics, including the ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to ...

Mounjaro, which is manufactured by Eli Lilly, has seen patients in trials lose up to 20% of their weight after 72 weeks of treatment. The study in Greater Manchester will look at how the drug works in ...

Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally ...